The Silent Architects: How Private Equity Is Rewriting the Rules of Pharmaceutical Commercialization

The Silent Architects: How Private Equity Rewrote the Rules of Pharmaceutical Commercialization

Private equity now controls billions in drug-launch infrastructure, market access platforms, and patient services firms. What that means for biopharma companies, healthcare providers, and — most critically — patients is a question the industry can no longer afford to sidestep.

Private equity has become one of the most consequential — and least scrutinized — forces reshaping how drugs reach patients. | Pharmaceutical Technology

When a private investment consortium paid $7.1 billion to take Syneos Health private in September 2023, most of the industry’s attention was on the deal size. What deserved more scrutiny was what Syneos actually does. It is an integrated biopharmaceutical solutions organization — the kind of company that handles drug commercialization, value demonstration, and market access on behalf of dozens of biopharma clients. In buying it, private equity did not acquire a drug. It acquired the machinery that gets drugs into the market.

That distinction matters enormously, and it defines the central story of private equity’s accelerating move into pharmaceuticals over the past decade. The headline narrative — “PE buys pharma companies” — misses the structural shift. The smarter money is not chasing molecules. It is buying the infrastructure layers between a drug’s regulatory approval and the patient’s hands. It is owning the contract development and manufacturing organizations (CDMOs), the market access platforms, the hub and patient services companies, the health economics consultancies, and the commercial analytics firms that big biopharma now depends on more than ever.

You should care about this because the consequences are not just financial. They reach into how drugs are launched, how their prices are defended, and ultimately, whether patients can afford and access them at all.

From Molecules to Machinery: Where PE Found Its Opening

Private equity’s traditional relationship with the pharmaceutical sector was cautious and largely transactional. Funds preferred acquiring companies with launched, revenue-generating branded or generic products, keeping their exposure to clinical-stage risk minimal. The math was simple: PE firms operate on defined hold periods, typically three to five years, and a drug still in Phase II trials offers neither the predictability nor the exit timeline that fits that model.

What changed was the structural transformation of the pharmaceutical industry itself. Starting in the early 2000s and accelerating through the 2010s, major pharmaceutical companies began exiting manufacturing. They ceded drug discovery to asset-light biotech firms. They outsourced regulatory affairs, pharmacovigilance, and commercialization to specialized service providers. The logic was efficiency and flexibility. The unintended consequence was the creation of an enormous, recurring-revenue services economy that PE investors found irresistible.

According to a detailed PitchBook analysis published in 2024, pharma services PE investment has become the hottest area of healthcare investing. The sector raised approximately $14 billion globally between 2012 and 2014. Between 2021 and 2023, that figure climbed to $59.4 billion. The number of deals nearly doubled: 432 transactions between 2017 and 2019 versus 774 between 2021 and 2023.

What makes pharma services attractive to PE is not just size — it is structure. These businesses generate predictable, contracted revenue from pharmaceutical clients who cannot easily switch vendors mid-program. They carry better margins than other healthcare segments. They face limited reimbursement risk. And unlike drug development itself, they do not go to zero when a clinical trial fails.

PE is not buying the science. It is buying the distribution, the data, and the access. That is a fundamentally different — and arguably more powerful — position in the value chain.

The CDMO Land Grab: Control Over Drug Manufacturing

No corner of pharma commercialization has attracted more PE capital than contract development and manufacturing organizations. CDMOs produce active pharmaceutical ingredients (APIs), formulate drug products, and in many cases manage packaging and distribution. They sit at the literal beginning of the supply chain and, without them, a drug approval is just paper.

The COVID-19 pandemic crystallized the strategic value of CDMOs for the entire industry. When the world watched Moderna and Pfizer produce billions of vaccine doses in under a year, what it was actually watching was a network of CDMOs, many of them PE-backed, operating at extraordinary speed and scale. Investor interest surged accordingly.

The pharmaceutical supply chain — from API manufacturing through commercialization — has become PE’s preferred terrain for investment. | Pharmaceutical Commerce

Consider the trajectory of specific deals. In 2023, Bain Capital acquired Fabbrica Italiana Sintetici (FIS), a family-owned Italian pharmaceutical services firm, for an estimated $1 billion. FIS had struggled through a rough period of debt and leadership transitions, but its 2,000 employees and 300 customers represented exactly the kind of scalable platform PE investors target for serial acquisition and build-out. Also in 2022, Astorg paid $2.6 billion for CordenPharma, specifically drawn by its lipid technologies used in mRNA vaccines — a clear bet on the long-term commercialization of next-generation therapeutics.

The playbook across these CDMO acquisitions is consistent. A PE firm acquires an anchor platform, installs professional corporate management — often replacing founder or family leadership that had governed through relationships rather than systems — then grows through add-on acquisitions that extend service capabilities. Bridgepoint acquired PharmaZell in 2020, then merged it with Novasep to create Axplora in 2022, a platform capable of supporting biopharma clients across the full drug lifecycle. The logic is vertical integration without the pipeline risk.

In 2025, the trend reached a new peak. Bain Capital, Kohlberg, Mubadala, and Partners Group combined to invest in PCI Pharma Services, a CDMO transaction that alone accounted for more than one-third of the entire year’s pharma services deal value by volume. According to Bain’s 2026 Global Healthcare Private Equity Report, 2025 marked the largest year on record for pharma services investment on a value basis.

Market Access: The New Battleground

If CDMO ownership is about controlling where drugs are made, market access is about controlling whether they get paid for. And in today’s pharmaceutical environment, where payer scrutiny is intensifying, prior authorization requirements are expanding, and the Inflation Reduction Act is fundamentally altering Medicare’s relationship to drug pricing, market access is no longer a back-office function. It is a core commercial determinant of a drug’s success or failure.

Private equity recognized this shift well before most biopharma companies did. Starting around 2020 and accelerating through 2022 and 2023, PE firms began aggressively acquiring specialized market access consultancies, health economics and outcomes research (HEOR) firms, payer analytics platforms, and hub and patient services companies.

A 2023 analysis by Houlihan Lokey listed the extent of PE penetration across the pharma commercialization services landscape. The findings were striking. Among the major commercialization companies it profiled:

• Amplity Health, a provider of outsourced medical and commercial teams, was backed by Altamont Capital Partners.
• Fishawack Health, a global commercialization partner spanning medical affairs and market access, was backed by Bridgepoint.
• Inizio, which operates across marketing, communications, and patient engagement for biopharma, carried PE backing.
• Lockwood, a medically focused communications firm, was backed by Ares Management.
• Fingerpaint Group, a full-service healthcare marketing and commercialization agency, was backed by Knox Lane.
• Genesis Research, a specialist HEOR and real-world evidence organization, operated with PE investment.
• ADVI, a market access and reimbursement strategy firm, was backed by Sheridan Capital.

This is not a coincidence of timing. It is a coordinated industry thesis. The combination of IRA price negotiation pressure, payer complexity, and the rise of cell and gene therapies — each requiring intricate reimbursement architecture — has created a permanent demand for specialized market access services. PE firms identified that demand early and built or bought the firms to supply it.

The downstream effects for biopharma companies are profound. When you outsource your market access strategy to a PE-backed firm, you are trusting that firm’s incentive structure aligns with your product’s long-term success. In the short-to-medium term, often it does. PE-backed commercialization firms have strong incentives to show measurable results for their biopharma clients. The concern emerges when sponsor-to-sponsor deal cycles shorten, when management teams rotate following exits, and when institutional knowledge built around your molecule walks out the door with a new ownership structure.

The IRA Effect: Pressure Creates Opportunity

The Inflation Reduction Act, signed into law in August 2022, altered the fundamental financial architecture of pharmaceutical commercialization in the United States. For the first time, Medicare gained the authority to negotiate drug prices directly with manufacturers. Small-molecule drugs became subject to negotiation after nine years of exclusivity; biologics after thirteen. The consequences rippled immediately through PE deal calculations.

The average cost of developing a drug from discovery through market for a top-20 global biopharma company was approximately $2.3 billion in 2022, according to Lincoln International’s analysis. Against that backdrop, the average expected return on investment for pharmaceutical R&D had already declined to a deeply uncomfortable 1.2 percent. IRA price ceilings on top of compressed returns created what Lincoln analysts called a permanent pressure on biopharma companies to identify the right price and defend it with compelling evidence — which, in turn, elevated the commercial value of the firms providing that evidence and defense.

BCG’s 2024 healthcare PE outlook noted that IRA implementation was likely to pull forward spending as biopharma companies accelerated their pricing and payer analyses, trying to maximize opportunities within exclusivity windows. That forward acceleration is a direct revenue tailwind for PE-backed market access firms. Some analysts at Bass Berry projected that biopharma and investor focus in 2024 would concentrate on pharma services companies offering dynamic solutions to clear the pathway for patient access and extend product viability through the full lifecycle.

The patient access landscape has become structurally complex — and PE-backed platforms are increasingly positioned as the solution providers. | Market Research Future

There is a real irony embedded in this dynamic. The IRA was designed, in significant part, to lower drug costs and improve patient access. Its enforcement mechanisms have, in practice, created a booming market for the specialized consultancies and technology platforms that help pharmaceutical companies navigate — and in some cases mitigate — those very mechanisms. Private equity, in this sense, profits from regulatory complexity regardless of which direction the regulatory pressure flows.

The Consolidation Wave and Its Competitive Consequences

PE’s preferred operational strategy in pharma services — buy a platform, grow it through add-on acquisitions, then exit to a strategic buyer or another fund — inevitably produces consolidation. And consolidation raises questions that antitrust regulators are only beginning to engage with seriously.

A 2025 analysis published by ProMarket examined how private equity investors can alter the incentives and behavior of pharmaceutical companies through two specific mechanisms: common ownership among rival firms and rollup acquisitions of smaller pharmaceutical businesses. The conclusion was direct: changes to a firm’s financial ownership structure have the potential to undermine competition, which in turn reduces consumer welfare.

This is not theoretical. Consider what happens when two nominally competing CDMO platforms are owned by affiliated funds within the same PE house, or when a market access consultancy firm advising multiple competing biopharma companies on pricing strategy is owned by a single financial sponsor. The conflicts are structural, not necessarily intentional. But the regulatory framework governing pharmaceutical mergers has historically focused on horizontal consolidation between direct competitors — it is poorly equipped to evaluate the more diffuse competitive effects of common ownership across the services layer.

Tom O’Connor, managing director and co-head of healthcare investment banking at Canaccord Genuity, told industry media in late 2023 that there was still approximately $3 billion in private equity money actively searching for pharma commercialization deals. He projected that deal volumes would accelerate into 2024 and that the pipeline for deals greater than $500 million in enterprise value for the following 18 months was easily double what it had been in the previous 12 to 18 months. That pipeline has largely materialized.

The Patient at the End of the Chain

Ask the industry’s defenders about PE’s role in pharma commercialization and they will cite efficiency gains, technology investment, and faster time to market for complex therapies. All of these claims have merit in specific contexts. PE-backed CDMOs did accelerate COVID-19 vaccine manufacturing. PE-backed data analytics firms have improved the precision of patient identification programs for rare disease therapies. PE investment in hub services has, in some documented cases, reduced the time between prescription and dispensing for specialty drugs.

What the defenders are less eager to address is the structural tension between PE’s financial model and patient access. The typical PE hold period is three to five years. Investment returns depend on improving EBITDA margins and achieving favorable exit multiples. In commercialization services, margin improvement often means labor rationalization — reducing the number of patient navigators, shortening call center hours, consolidating therapeutic area expertise. None of these decisions are inherently predatory. But they compound over multiple ownership cycles in ways that affect real patients navigating already complex systems.

The data on prior authorization burdens is instructive. A 2024 regulatory burden survey found that 89 percent of medical practices rated prior authorization as very or extremely burdensome. Ninety-seven percent reported that their patients had experienced care delays or denials due to prior authorization requirements. The number of drugs on PBM exclusion lists grew from a handful a decade ago to over 600 by 2024. These are systemic failures of the pharmaceutical distribution and coverage architecture — an architecture that PE-backed companies increasingly sit at the center of, as both service providers to biopharma clients and, in some cases, as investors in the pharmacy benefit management and specialty pharmacy segments themselves.

The question is not whether private equity should participate in pharmaceutical commercialization. It already does, at scale. The question is whether the current regulatory and disclosure architecture is fit for that reality.

Interfaith Center on Corporate Responsibility shareholders filed proposals at seven major pharmaceutical companies in late 2023, arguing that current business models, which in many instances prioritize profitability over patient health, often infringe on fundamental human rights to healthcare access. Those proposals were directed at publicly traded companies. The PE-backed layer of the commercialization chain — the CDMOs, the market access firms, the hub services companies — operates almost entirely outside the scope of such shareholder engagement.

Technology as the New Moat

Where the next wave of PE investment in pharma commercialization is headed is already visible in deal patterns. AI-enabled analytics platforms, real-world data companies, and direct-to-patient service infrastructure are attracting disproportionate capital. The thesis is straightforward: as drug complexity increases — cell and gene therapies, antibody-drug conjugates, radiopharmaceuticals — and as patient populations become smaller and more precisely defined, the commercial value of technology-enabled platforms that can identify, reach, and serve those patients grows substantially.

Eversana, one of the larger PE-influenced commercialization firms operating in the U.S., publicly described a strategy of developing a proprietary AI infrastructure it calls “pharmatizing” AI, including a collaboration with Google’s Gemini for AI-based marketing agency capabilities and an Amazon collaboration for AI-supported medical, legal, and regulatory review workflows. Knipper Health, which received a mid-2024 investment from PE firm Frazier Healthcare, moved aggressively into direct-to-patient platform capabilities, reporting significant improvement in patient conversion rates compared to the traditional retail pharmacy channel.

OptimizeRx’s $95 million acquisition of Medicx Health and Nordic Capital’s majority stake acquisition in IntegriChain, a commercialization and market access platform, from Accel-KKR in late 2023 — both signaled the direction of travel. These are not manufacturing or clinical trial site investments. They are data, digital reach, and market intelligence plays. PE firms are betting that the firms controlling the data and digital infrastructure of drug commercialization will be the critical bottlenecks of the next decade, and that owning those bottlenecks at scale is worth the premium.

What Biopharma Executives Need to Understand

If you lead a biopharma company — whether a mid-size specialty pharma approaching a major launch or a smaller biotech preparing for its first commercial program — your relationship with PE-backed service providers is not simply a vendor management question. It is a strategic dependency that deserves board-level scrutiny.

Several questions your leadership team should be asking about every major PE-backed service provider in your commercialization chain:

• What is the current sponsor’s investment thesis, and at what stage of the hold period are they? A firm that bought an asset in 2021 and plans to exit by 2025 or 2026 may be managing for margin, not innovation.
• What is the continuity plan for key personnel and institutional knowledge specific to your molecule if the firm changes ownership during your launch window?
• Does the firm have other clients whose competitive interests conflict with yours, and what governance structures address that conflict?
• How does the technology infrastructure the firm uses — data platforms, patient databases, analytics tools — transfer or terminate if you need to change providers mid-program?
• Is the firm’s EBITDA pressure leading to underinvestment in the front-line patient services staff who represent your brand to patients and prescribers every day?

These are not hostile questions. They are the normal due diligence of an industry that has outsourced increasing portions of its most critical commercial functions to financial sponsors operating on a fundamentally different time horizon.

A Reckoning That Has Not Yet Arrived

Private equity’s transformation of pharmaceutical commercialization is a story in the middle of its arc. The capital deployment phase — in CDMOs, in market access, in data and analytics — is mature. The exit phase is beginning. Firms that bought commercialization assets in 2020 and 2021 at peak multiples are facing a more challenging exit environment, one where buyer valuation expectations have adjusted downward and where sponsor-to-sponsor deal liquidity is still recovering from the 2022 and 2023 contraction.

The regulatory reckoning has not yet arrived, but it is approaching. The FTC’s attempted blockade of IQVIA’s acquisition of pharma digital advertising firm Propel Media in 2023 was one signal. The broader scrutiny of healthcare PE that academic economists and antitrust researchers are now publishing with increasing frequency is another. ProMarket’s conclusion — that changes to a firm’s financial ownership structure have the potential to undermine competition — will eventually find its way into agency thinking, even if the translation from academic argument to enforcement action takes years.

What the industry should not do is wait for that reckoning passively. The biopharma companies that will navigate this environment most effectively are those that build in-house capabilities where the commercial function is genuinely core and proprietary, select PE-backed partners with discipline and transparency, and insist on contractual protections that survive ownership transitions. The ones that treat PE-backed providers as interchangeable commodities will find themselves exposed when the music stops on any particular ownership cycle.

Private equity did not create the structural complexity of pharmaceutical commercialization. Regulatory proliferation, payer sophistication, and the scientific advance into harder-to-develop therapies did that. PE capital moved into the infrastructure gaps that complexity created, bringing both real operational capability and real conflicts of interest. Acknowledging both of those realities simultaneously is the minimum standard for anyone who wants to understand what the pharmaceutical industry is actually becoming, and where your products, your organizations, and your patients sit within it.

· · ·

References

1. GlobalData / Pharmaceutical Technology — Q3 2024 update: private equity deals in pharmaceutical in the US https://www.pharmaceutical-technology.com/data-insights/theus-privateequity-activity-pharmaceutical-industry/
2. Healthcare Brew — Why private equity investors are going all in on the pharma services sector (PitchBook analysis, July 2024) https://www.healthcare-brew.com/stories/2024/07/11/why-private-equity-investors-are-going-all-in-on-the-pharma-services-sector
3. C&EN (Chemical & Engineering News) — Private equity ramps up in pharmaceutical services https://cen.acs.org/business/outsourcing/Private-equity-ramps-pharmaceutical-services/101/i34
4. Bain & Company — Biopharma: Healthcare Private Equity Scores a Record Year in Deal Value (2023 Global Healthcare PE and M&A Report) https://www.bain.com/insights/biopharma-global-healthcare-private-equity-and-ma-report-2023/
5. Bain & Company — Playing the Long Game in Pharma Services (2026 Global Healthcare Private Equity Report) https://www.bain.com/insights/playing-the-long-game-in-pharma-services-global-healthcare-private-equity-report-2026/
6. Lincoln International — What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access https://www.lincolninternational.com/perspectives/articles/what-price-is-right-trends-and-opportunities-for-private-equity-in-pharma-market-access/
7. MM+M Online — Signs point to upturn in pharma commercialization M&A in 2024 (Canaccord Genuity analysis) https://www.mmm-online.com/home/channel/7-day-supply/pharma-commercialization-merger-acquisition-2024/
8. Bass Berry — 2024 Healthcare Private Equity Outlook & Trends in M&A https://www.bassberry.com/news/2024-healthcare-private-equity-outlook-trends/
9. BCG — The 2024 Outlook for Private Equity in US Health Care https://www.bcg.com/publications/2024/private-equity-in-health-care-2024
10. Houlihan Lokey — PHARMA COMMERCIALIZATION: A Deep Dive in Market Access (Summer 2023 Whitepaper) https://hl.com/media/5ryessqp/houlihan-lokey-pharma-market-access-whitepaper-aug-2023.pdf
11. ProMarket — Do Private Equity and Other Investors Harm Competition in the Pharmaceutical Industry? https://www.promarket.org/2025/05/15/do-private-equity-and-other-investors-harm-competition-in-the-pharmaceutical-industry/
12. Pharmaceutical Commerce — The Key to Connecting with Patients: Pharma’s Market Access Transformation https://www.pharmaceuticalcommerce.com/view/the-key-to-connecting-with-patients-pharma-s-market-access-transformation
13. Interfaith Center on Corporate Responsibility — 2024 Shareholder Proposals at Pharma Companies Cite Strategies to Keep Drug Prices High as Potential Human Rights Risks https://www.iccr.org/2024-shareholder-proposals-at-pharma-companies-cite-strategies-to-keep-drug-prices-high-as-potential-human-rights-risks/
14. Remap Consulting — Reflecting on the Pricing and Market Access Trends that Shaped 2024 https://remapconsulting.com/pma-trends/reflecting-on-the-pricing-and-market-access-trends-that-shaped-2024/
15. PHIL.us — 5 Trends Set to Impact Patient Access to Prescription Therapy in 2024 https://phil.us/5-trends-set-to-impact-patient-access-to-prescription-therapy-in-2024/
16. Drug Discovery Trends / WTWH Media — Pharma M&A activity primed for another high-flying year in 2024 https://www.drugdiscoverytrends.com/pharma-ma-activity-primed-for-another-high-flying-year-in-2024/

This article is intended for informational and editorial purposes. All figures cited are sourced from publicly available industry research. No investment advice is expressed or implied.